SGLT2 inhibitor and GLP-1 receptor agonist combination therapy substantially improved the renal function in a patient with type 2 diabetes: Implications for additive renoprotective effects of the two drug classes

Kenta Nonomura; Katsumi Iizuka; Yayoi Kuwabara-Ohmura; Daisuke Yabe

doi:10.2169/internalmedicine.4323-19

SGLT2 inhibitor and GLP-1 receptor agonist combination therapy substantially improved the renal function in a patient with type 2 diabetes: Implications for additive renoprotective effects of the two drug classes

Kenta Nonomura
, Katsumi Iizuka
, Yayoi Kuwabara-Ohmura
, Daisuke Yabe

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

A 72-year-old man had type 2 diabetes (T2D) that had been diagnosed at 54 years old. Macroalbuminuria was first detected at age 64. While his HbA1c had been kept below 7%, his estimated glomerular filtration rate (eGFR) was declining rapidly. At 70 years old, his eGFR dropped below 50 mL/min/1.73 m2. A renal biopsy revealed diabetic nephropathy. Sodium glucose transporter 2 inhibitors (SGLT2i)/glucagon-like peptide-1 receptor agonists (GLP-1RA) combination therapy substantially improved his eGFR and urinary albumin level, and the renoprotective effect persisted for the two-year study period. These findings suggest that SGLT2i and GLP-1RA can additively improve the renal function in patients with T2D.

Original language	English
Pages (from-to)	1535-1539
Number of pages	5
Journal	Internal Medicine
Volume	59
Issue number	12
DOIs	https://doi.org/10.2169/internalmedicine.4323-19
Publication status	Published - 15-06-2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Internal Medicine

Access to Document

10.2169/internalmedicine.4323-19

Fingerprint

Dive into the research topics of 'SGLT2 inhibitor and GLP-1 receptor agonist combination therapy substantially improved the renal function in a patient with type 2 diabetes: Implications for additive renoprotective effects of the two drug classes'. Together they form a unique fingerprint.

Cite this

@article{85ebe51d72e745f9a0a3267526a81dae,

title = "SGLT2 inhibitor and GLP-1 receptor agonist combination therapy substantially improved the renal function in a patient with type 2 diabetes: Implications for additive renoprotective effects of the two drug classes",

abstract = "A 72-year-old man had type 2 diabetes (T2D) that had been diagnosed at 54 years old. Macroalbuminuria was first detected at age 64. While his HbA1c had been kept below 7\%, his estimated glomerular filtration rate (eGFR) was declining rapidly. At 70 years old, his eGFR dropped below 50 mL/min/1.73 m2. A renal biopsy revealed diabetic nephropathy. Sodium glucose transporter 2 inhibitors (SGLT2i)/glucagon-like peptide-1 receptor agonists (GLP-1RA) combination therapy substantially improved his eGFR and urinary albumin level, and the renoprotective effect persisted for the two-year study period. These findings suggest that SGLT2i and GLP-1RA can additively improve the renal function in patients with T2D.",

keywords = "Diabetic kidney disease, Estimated glomerular filtration rate, GLP-1 receptor agonist, SGLT2 inhibitor, Type 2 diabetes mellitus",

author = "Kenta Nonomura and Katsumi Iizuka and Yayoi Kuwabara-Ohmura and Daisuke Yabe",

note = "Publisher Copyright: {\textcopyright} 2020 The Japanese Society of Internal Medicine.",

year = "2020",

month = jun,

day = "15",

doi = "10.2169/internalmedicine.4323-19",

language = "English",

volume = "59",

pages = "1535--1539",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "12",

}

Nonomura, K, Iizuka, K, Kuwabara-Ohmura, Y & Yabe, D 2020, 'SGLT2 inhibitor and GLP-1 receptor agonist combination therapy substantially improved the renal function in a patient with type 2 diabetes: Implications for additive renoprotective effects of the two drug classes', Internal Medicine, vol. 59, no. 12, pp. 1535-1539. https://doi.org/10.2169/internalmedicine.4323-19

SGLT2 inhibitor and GLP-1 receptor agonist combination therapy substantially improved the renal function in a patient with type 2 diabetes: Implications for additive renoprotective effects of the two drug classes. / Nonomura, Kenta; Iizuka, Katsumi; Kuwabara-Ohmura, Yayoi et al.
In: Internal Medicine, Vol. 59, No. 12, 15.06.2020, p. 1535-1539.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - SGLT2 inhibitor and GLP-1 receptor agonist combination therapy substantially improved the renal function in a patient with type 2 diabetes

T2 - Implications for additive renoprotective effects of the two drug classes

AU - Nonomura, Kenta

AU - Iizuka, Katsumi

AU - Kuwabara-Ohmura, Yayoi

AU - Yabe, Daisuke

PY - 2020/6/15

Y1 - 2020/6/15

N2 - A 72-year-old man had type 2 diabetes (T2D) that had been diagnosed at 54 years old. Macroalbuminuria was first detected at age 64. While his HbA1c had been kept below 7%, his estimated glomerular filtration rate (eGFR) was declining rapidly. At 70 years old, his eGFR dropped below 50 mL/min/1.73 m2. A renal biopsy revealed diabetic nephropathy. Sodium glucose transporter 2 inhibitors (SGLT2i)/glucagon-like peptide-1 receptor agonists (GLP-1RA) combination therapy substantially improved his eGFR and urinary albumin level, and the renoprotective effect persisted for the two-year study period. These findings suggest that SGLT2i and GLP-1RA can additively improve the renal function in patients with T2D.

AB - A 72-year-old man had type 2 diabetes (T2D) that had been diagnosed at 54 years old. Macroalbuminuria was first detected at age 64. While his HbA1c had been kept below 7%, his estimated glomerular filtration rate (eGFR) was declining rapidly. At 70 years old, his eGFR dropped below 50 mL/min/1.73 m2. A renal biopsy revealed diabetic nephropathy. Sodium glucose transporter 2 inhibitors (SGLT2i)/glucagon-like peptide-1 receptor agonists (GLP-1RA) combination therapy substantially improved his eGFR and urinary albumin level, and the renoprotective effect persisted for the two-year study period. These findings suggest that SGLT2i and GLP-1RA can additively improve the renal function in patients with T2D.

KW - Diabetic kidney disease

KW - Estimated glomerular filtration rate

KW - GLP-1 receptor agonist

KW - SGLT2 inhibitor

KW - Type 2 diabetes mellitus

UR - https://www.scopus.com/pages/publications/85086522873

UR - https://www.scopus.com/pages/publications/85086522873#tab=citedBy

U2 - 10.2169/internalmedicine.4323-19

DO - 10.2169/internalmedicine.4323-19

M3 - Article

C2 - 32188813

AN - SCOPUS:85086522873

SN - 0918-2918

VL - 59

SP - 1535

EP - 1539

JO - Internal Medicine

JF - Internal Medicine

IS - 12

ER -

SGLT2 inhibitor and GLP-1 receptor agonist combination therapy substantially improved the renal function in a patient with type 2 diabetes: Implications for additive renoprotective effects of the two drug classes

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this